Given the disparate cell-type dependent actions of EP4, it has been unclear what the global consequences of pharmacological EP4 (ant)agonism may be in kidney disease, with effects appearing to be at least in part dependent upon the model and agents employed. Here, PTGER4 is linked to kidney disorder.